Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite

Overview[ - collapse ][ - ]

Purpose The purpose of this study is to examine wether the combination of Ramatroban/Montelukast is as effective as Montelukast alone in patients with mild to moderate atopic asthma (GINA I and II) sensitive to house dust mite. The test is performed by a specific inhalative provocation.
ConditionAsthma
InterventionDrug: ramatroban
Drug: montelukast
PhasePhase 2/Phase 3
SponsorResearch Center Borstel
Responsible PartyResearch Center Borstel
ClinicalTrials.gov IdentifierNCT00311051
First ReceivedApril 1, 2006
Last UpdatedApril 13, 2012
Last verifiedApril 2012

Tracking Information[ + expand ][ + ]

First Received DateApril 1, 2006
Last Updated DateApril 13, 2012
Start DateApril 2005
Estimated Primary Completion DateApril 2007
Current Primary Outcome Measures
  • Lung function by spirometry
  • Allergen concentration for specific bronchoprovocation
Current Secondary Outcome MeasuresBlood level of thromboxane and leukotriene metabolite

Descriptive Information[ + expand ][ + ]

Brief TitleRamatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite
Official TitleA Randomized Double-blind and Placebo-controlled Study to the Influence of Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Patients With Mild to Moderate Atopic Asthma (House Dust Mite)
Brief Summary
The purpose of this study is to examine wether the combination of Ramatroban/Montelukast is
as effective as Montelukast alone in patients with mild to moderate atopic asthma (GINA I
and II) sensitive to house dust mite. The test is performed by a specific inhalative
provocation.
Detailed Description
In the early allergic response in asthma, allergens connect to IgE on mast cells and
basophile granulocytes. For that there are 3 main pathways in activation:

Besides quick liberation of Histamine and induction of cytokines there is a liberation of
mediators from the arachidonate metabolism. In addition to Histamine there are especially
Prostaglandin PGD2, Leukotriene LTC4 and also Thromboxane A2 for the classic symptoms of the
early allergic reaction responsible. All of those mediators have potent bronchoconstrictive
activity.

Prostaglandin D2 and Thromboxane A2 work on Thromboxane receptors. LTC4 links to
Cys-LT-receptors.

According to an in-vitro-model of the early allergic reaction in human precision-cut lung
slices with passive specific sensitization against grass-pollen, it has been shown that the
early allergic response can only be suppressed partly by giving Antihistamines, Leukotriene
receptor antagonists or Thromboxane receptor antagonist all on its own. It goes in consent
with clinical findings, that all of these drugs alone have just an insufficient activity on
asthma.

In the described human in-vitro-model the combination of Thromboxane receptor antagonist
with Leukotriene receptor antagonist (Montelukast) blocked the early response in asthma
completely.

These findings are the rationale for our study because so far there is no clinical data
about the effect of the combination of Leukotriene receptor antagonist (Montelukast) with
Thromboxane receptor antagonist.

The drug Montelukast is a Leukotriene receptor antagonist which is known for the treatment
of mild to moderate asthma in Germany. According to the GINA-Guidelines Montelukast is given
in addition to steroids and β-mimetics in asthma severity grade II and III.

The drug Ramatroban is a Thromboxane A2 receptor antagonist which is in Japan allowed for
the treatment of allergic rhinitis. It also has an anti-asthmatic effect because it blocks
bronchoconstriction, hyperresponsiveness of the airways and infiltration of inflammation
cells. Furthermore, it has positive effects on allergic rhinitis by blocking the
permeability of capillaries, blocking the nasal hyperresponsiveness and the infiltration of
the mucosa by eosinophils.

During the studies Ramatroban has proved to be a save drug for the indication allergic
rhinitis and also allergic asthma. In contrast to sufficient effectiveness in the indication
allergic rhinitis it has been said that there is just insufficient effectiveness in the
indication asthma.

About the combination of Ramatroban and Montelukast exists no clinical data so the study at
hand examines the effect of Ramatroban/Montelukast versus Montelukast/Placebo on the early
allergic reaction in patients with mild to moderate atopic asthma (GINA I and II) sensitive
to house dust mites in a specific inhalative provocation.
Study TypeInterventional
Study PhasePhase 2/Phase 3
Study DesignAllocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
ConditionAsthma
InterventionDrug: ramatroban
Drug: montelukast
Study Arm (s)Not Provided

Recruitment Information[ + expand ][ + ]

Recruitment StatusWithdrawn
Estimated EnrollmentNot Provided
Estimated Completion DateApril 2007
Estimated Primary Completion DateNot Provided
Eligibility Criteria
Inclusion Criteria:

- Atopic (house dust mite) asthma

- Severity GINA one and two

Exclusion Criteria:

- No reaction in specific bronchial provocation test

- Other kind of clinical relevant atopic reaction
GenderBoth
Ages18 Years
Accepts Healthy VolunteersNo
ContactsNot Provided
Location CountriesGermany

Administrative Information[ + expand ][ + ]

NCT Number NCT00311051
Other Study ID NumbersRAMONA-4022229
Has Data Monitoring CommitteeNot Provided
Information Provided ByResearch Center Borstel
Study SponsorResearch Center Borstel
CollaboratorsNot Provided
Investigators Principal Investigator: Peter Zabel, Prof. Research Center Borstel
Verification DateApril 2012

Locations[ + expand ][ + ]

Research Center Borstel
Borstel, Germany, 23845